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Gender Male 853 (48.5%) 
Female 906 (51.5%) 
Age Median (IQR) 14 years (7-33) 
Age Group Early Years (0-4 years) 307 (17.5%) 
Primary School (5-10 years) 357 (20.3%) 
Secondary School (11-18 
years) 360 (20.5%) 
Adults (19-66 years) 684 (38.9%) 
Retirement Age Adults (67+) 51 (2.9%) 
Education and 
Employment 
In formal education 776 (44.1%) 
Working from home 238 (13.5%) 
Working outside home 133 (7.6%) 
Neither in education or formal 
employment 612 (34.8%) 
Self Reported 
Comorbidities 
Asthma 11 (0.6%) 
COPD 2 (0.1%) 
Hypertension 31 (1.8%) 
Diabetes 21 (1.2%) 
Cardiovascular Disease 9 (0.5%) 
Chronic Kidney Disease 1 (0.1%) 
Dementia 0 (0%) 
 
 











Supplementary Figure 1. Log normalised antibody titres against spike, receptor binding           
domain and nucleocapsid antigens by time since self-reported COVID-19 symptoms. ​Values           





3. Antibody Seroprevalence by antibody target and age group  
 
Supplementary Table 2: Age stratified seroprevalence.  
 
 
4. Positive and negative predictive value of symptoms by age group 
 
 
Supplementary Table 2: Positive and negative predictive values stratified by age for            
symptoms reported as COVID-19-like illness. PPV = positive predictive value, NPV =            
negative predictive value. 
 
5. Sensitivity Analysis 
 
In a sensitivity analysis in which the threshold for spike positivity was doubled,             
seroprevalence was 49.7%. 
 
 









Early Years (0-4 years) 27.6% 
(20.8-35.6%) 
22.4% (16.2 - 
30.0%) 
18.4% (12.8 - 
25.7%) 
Primary School (5-10 years) 56.4% 
(49.8-62.7%) 




















 Fever Cough 
Loss of Smell or 
Taste 
Age Group PPV NPV PPV NPV PPV NPV 
Overall 79.0% 38.3% 81.6% 43.6% 94.1% 42.7% 
Early Years (0-4 years) 33.3% 68.2% 36.4% 76.1% 33.3% 68.1% 
Primary School (5-10 
years) 57.1% 42.9% 65.2% 48.3% 100% 44.6% 
Secondary School (11-18 
years) 63.0% 25.0% 73.0% 28.0% 88.9% 29.1% 
Adults (19-66 years) 90.9% 31.0% 91.4% 35.9% 96.6% 37.1% 
Retirement Age Adults 














6. Population Structure 
 
 
Supplementary Figure 2. Population age structure for survey respondents compared          























7. Consort Diagram  
 
 
Supplementary Figure 3. Consort diagram showing enrollment of both the randomly           
selected and the enriched households into the study 
 
